Catalyst stock: buy or sell?

CBIO stock price: $7.08 3.66% At close on February 21st, 2020

Updated on:
February 21st, 2020


After breaking up the SMA line of 200 days yesterday, Catalyst shares closed today at $7.08. On February/13 CBIO plummed a scary -22.92%.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications.

Should I buy Catalyst stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading strategy that matches with your character as inversor. At, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Catalyst stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Catalyst Biosciences stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't find any rating for CBIO stock for the last 30 days.

Catalyst stock analysis

Daily outlook

After breaking up the simple moving average line of 200 days yesterday, Catalyst closed today at $7.08.

After crossing up the SMA line of 200d yesterday, Catalyst closed at $7.08, climbed a 3.66%. Since SMA50d and SMA100d crossed up on Jan/13, CBIO price climbed $0.36 per share (5.36%).

CBIO stock chart (daily)

Weekly outlook

Catalyst Biosciences shares broke up the simple moving average line of 200d, closing at $7.08. Last week CBIO collapsed a frightening -29.73% in just one week.

Since SMA10d and SMA20w crossed up early January, CBIO price climbed $0.55 per share (8.42%).

CBIO stock chart (weekly)

Catalyst stock price history

Catalyst IPO was on April 12th, 2006 at $701.69 per share1. Since then, CBIO stock sliced a -99.00%, with a yearly average of -7.60%.

1: Adjusted price after possible price splits or reverse-splits.

Catalyst stock historical price chart

CBIO stock reached 52-week highs on April at $10.84, and all-time highs 2011-03-01 with a price of 2375.63.

Catalyst stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not detected any price prediction for Catalyst stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

Catalyst presented brilliant results for 2018-Q4 on March. Catalyst Biosciences skyrocketed Earnings per Share (EPS) by 23.00%, beating experts estimates of $-0.74. Catalyst Biosciences posted $-0.91.
CBIO earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual revenues report draw a spooky correction of -99.41% to $0.01 M USD. In the same way, its income margin (compared to sales) plunged to -500,916.67%, that is $-30.06 million.

CBIO annual Sales and Income evolution
2013$3.54 M-$-46.71 M-1319.5%-
2014$0.28 M-92.23%$-32.62 M-11862.9%-30.16%
2015$1.75 M536.36%$-14.76 M-843.5%-54.75%
2016$0.40 M-77.20%$-16.95 M-4246.9%14.79%
2017$1.02 M155.14%$-21.56 M-2118.0%27.24%
2018$0.01 M-99.41%$-30.06 M-500916.7%39.40%

Quarterly financial results

Reported quarter income marked $-10.84 million with a profit margin of . Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Catalyst sales marked a frightening decrease and collapsed a -100.00%. Looking back to recent quarterly results, Catalyst posted 5 negative quarters in a row.
CBIO quarterly Sales and Income evolution
2017-Q1$0.27 M-$-4.14 M-1527.7%-
2017-Q2$0.11 M-59.04%$-5.88 M-5297.3%42.03%
2017-Q3$0.32 M186.49%$-5.79 M-1821.7%-1.48%
2017-Q4$0.32 M0.00%$-5.75 M-1809.1%-0.69%
2018-Q1$0.01 M-98.11%$-5.04 M-84033.3%-12.36%

Catalyst ownership

When you are planning to invest in a company, it's always worth to have a look its ownership structure.

Catalyst shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 7.82% of all shares.

In case of Catalyst stock, 66.71% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CBIO stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Catalyst Biosciences:

Market cap$85.2 M
Total shares12.0 M
Float shares7.0 M
  - Institutional holdings (%)66.7%
  - Insider holdings (%)7.8%
Shares in short selling0.0%

Catalyst summary

Friday, February 21st, 2020
Day range$6.59 - $7.34
Previous close$6.83
Session gain3.66%
Average true range$0.64
50d mov avg$6.80
100d mov avg$6.10
200d mov avg$6.78
Daily pattern
Weekly pattern

Catalyst performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Catalyst performance to :
CBIOCatalyst Bioscien...27.80%3.96%-15.31%

Catalyst competitors

Unfortunately, we could not find any public company that could be defined as Catalyst Biosciences competitor. This doesn't mean Catalyst Biosciences does not have any competitor in the market, it's just we could not detected it.